Press Room - Sanofi US News
WEB5 days ago · Dr. Fox is a paid advisor to Sanofi for the HERCULES trial. Based on preliminary analysis of the HERCULES study, there was a slight increase in tolebrutinib-treated patients of some adverse events. Liver enzyme elevations (>3xULN) were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group, a …
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB4 days ago · Sanofi’s safety and tolerability analysis showed 4.1% of people on tolebrutinib had liver enzyme levels of at least three times the upper limit of normal, compared to 1.6% of the patients taking ...
Sanofi's tolebrutinib cuts MS progression by 31% in trial
WEB4 days ago · Sanofi revealed the top-line result from HERCULES a few weeks ago, noting that tolebrutinib is the only drug in the oral BTK inhibitor class to have shown an improvement in disability progression ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB4 days ago · FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
WEBFeb 23, 2022 · New data for tolebrutinib, Sanofi’s investigational oral Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of multiple sclerosis (MS), showed a significant effect on key immune mediators that may drive disease progression within the CNS.
Tolebrutinib clinical trial program update - Sanofi
WEBAug 8, 2022 · The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain unchanged with submission in relapsing MS expected in 2024.
Press Room - Sanofi US News
WEBFeb 24, 2022 · Tolebrutinib is an investigational brain-penetrant Bruton’s tyrosine kinase inhibitor that achieves CSF concentrations needed for targeting B lymphocytes and microglial cells.
Sanofi eyes approval after MS therapy slows disease progression …
WEB4 days ago · Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS),. The results from the HERCULES Phase III trial (NCT04411641) showed that Bruton tyrosine kinase (BTK) inhibitor delayed the time to six-month disability progression by 31% compared to placebo.
Sanofi's Tolebrutinib Delays Disability Progression In Patients …
WEB4 days ago · Friday, Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that ...
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
WEBSep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis. Houman Ashrafian, MD, PhD. Sanofi has announced topline data from its phase 3 HERCULES study (NCT04411641) of its ...